E

Enliven Therapeutics
D

ELVN

20.045
USD
-0.62
(-2.98%)
مفتوح الان
حجم التداول
247
الربح لكل سهم
-2
العائد الربحي
-
P/E
-10
حجم السوق
1,187,376,540
أصول ذات صلة المقالات

العنوان: Enliven Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.